Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.88 +0.12 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
From GSK plc
Via Business Wire
7 Retirement Stocks to Buy in July
Planning for retirement can feel overwhelming in bear markets, but these seven retirement stocks can provide a boost to savings. Caterpillar (CAT): The 
Via InvestorPlace
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
From GSK plc
Via Business Wire
GSK Shares Encouraging Data From Chronic Hepatitis B Candidate
Via Benzinga
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
Key Takeaways: Laekna is seeking a Hong Kong IPO to raise funds to accelerate the commercialize two core products licensed from Novartis The company currently is not generating... 
Via Benzinga
Best Stocks For 2022 Recession
Recession is in the air in 2022, and I have 3 stocks for recession-proofing your portfolio. Let's look at Walmart, Raytheon Tech, and GlaxoSmithKline. 
Via Talk Markets
Antibiotic Makers Adopt Their Own Environmental Safeguard Standards
Via Benzinga
GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate
Via Benzinga
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes
The companies' shot was more than 93% effective in previously infected people. 
Via Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Reuters 
Via Benzinga
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... 
Via Benzinga
FDA Approves GSK's Measles Vaccine
Via Benzinga
Analyzing GSK's Short Interest
GSK's (NYSE:GSK) short percent of float has fallen 17.24% since its last report. The company recently reported that it has 6.02 million shares sold short, which is 0.24% of all... 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, June 13
CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why 
Via Benzinga
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, June 10
Reuters Rebranded McDonald’s Restaurants To Reopen In Russia 
Via Benzinga
Breakthroughs In Treating Killer Diseases Could Lengthen Life
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer’s, neonatal... 
Via FinancialNewsMedia
Topics Death
Exposures Death
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
From GSK plc
Via Business Wire
Morning Brief: Top Financial Stories Dominating on Monday, June 6
Reuters 
Via Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
Week In Review: Vivo Raises $600 Million In First Tranche Of China PE Fund
Vivo Capital held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. Meanwhile, ProfoundBio closed a $70 million Series A+... 
Via Talk Markets
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
3 Undervalued Dividend Growth Stocks
Investors who focus on a strategy of dividend growth stocks have performed better than some broader stock market indices. 
Via InvestorPlace
GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know
Close on the heels of an M&A deal, GlaxoSmithKline plc (NYSE: GSK) confirmed the spin-off of the consumer healthcare business it jointly owns with U.S. pharma giant Pfizer, Inc. 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Wednesday, June 1
Reuters Redbird Capital Buys Italian Football Club AC Milan 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.